RxDoctor Payments Data

Ithan Peltan, MD

Pulmonary Disease · Murray, UTNPI 1558598003

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $329 of the $341 with a category attached, or 96.3%. Novartis accounts for 96.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for pulmonary disease clinicians in UT, where the typical reported total is $297.

$341in general payments, 2019–2025

Across 2 payments — averaging $170.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$329
  • Merck$13
$1,075,541in research payments, 2019–2025

Across 41 payments — averaging $26,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$833K
  • Novartis$242K

What the payments were for

  • Travel & lodging$32996%
  • Education$134%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis1$329
Merck1$13

How this compares

$341 in reported general payments places this provider in the 50th percentile of 101 pulmonary disease providers in Utah.

See all pulmonary disease providers in Utah

Medicare billing

Part B allowed, 2024
$14,125
Medicare patients
51
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →